HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Anderson, K. M. Articles by Topol, E. J. Search for Related Content PubMed PubMed Citation Articles by Anderson, K. M. Articles by Topol, E. J.

Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention

Keaven M. Anderson, PhD^*, Robert M. Califf, MD, FACC, Gregg W. Stone, MD, FACC^**, Franz-Josef Neumann, MD, FACC^||, Gilles Montalescot, MD^¶, Dave P. Miller, MS, James J. Ferguson, III, MD, FACC, James T. Willerson, MD, FACC, Harlan F. Weisman, MD, FACC^* and Eric J. Topol, MD, FACC

^* Centocor, Malvern, Pennsylvania, USA
Duke University, Durham, North Carolina, USA
Texas Heart Institute, Houston, Texas, USA
Lewin-TAG, Inc., San Francisco, California, USA
^|| Deutsches Herzzentrum, Munich, Germany
^¶ Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France
^** Lenox Hill Hospital, New York, New York, USA
Cleveland Clinic Foundation, Cleveland, Ohio, USA

View larger version (20K): [in a new window]   Figure 1 Mortality over six months for all studies combined by patient randomization to standard therapy (placebo) versus standard therapy plus abciximab bolus within 1 h before percutaneous coronary intervention followed by a 12-h infusion.

View larger version (30K): [in a new window]   Figure 2 Difference in one-year mortality in the EPIC, EPILOG and EPISTENT trials by randomized treatment assignment partitioned among patients with and without an early end point event (death, myocardial infarction or urgent percutaneous coronary intervention or coronary artery bypass grafting within 48 h of of randomization). Solid box = with event < 48 h; open box = without event < 48 h. For acronym definitions, see Abbreviations and Acronyms box.